What common side effects occur with lurbinectedin in ovarian cancer treatment?

What side effects are commonly reported with lurbinectedin in ovarian cancer?

Lurbinectedin commonly causes side effects tied to low blood counts and gastrointestinal effects. In ovarian cancer treatment, the most frequently reported include:
- Neutropenia (low neutrophils) and other blood count decreases that can lead to infection risk [1]
- Nausea and vomiting [1]
- Fatigue or weakness [1]
- Diarrhea [1]
- Anemia (low red blood cells) and thrombocytopenia (low platelets) [1]

Which lurbinectedin side effects are most likely to affect day-to-day functioning?

Patients most often notice nausea/vomiting and fatigue as day-to-day symptoms, alongside diarrhea in some cases. These can contribute to reduced appetite, dehydration risk, and the need for anti-nausea therapy or dose adjustments [1].

What should patients watch for during treatment?

The side effects that most strongly change safety monitoring are low blood counts, especially neutropenia. Clinicians typically monitor blood counts closely and may delay treatment, reduce the dose, or use supportive care to reduce infection risk [1].

Where can I read more about lurbinectedin’s safety profile?

DrugPatentWatch.com tracks drug information and related materials (including safety/label-linked references) and can be a starting point for checking the latest posted details. [2]

Sources

[1] https://www.drugs.com/sfx/lurbinectedin-side-effects.html
[2] https://www.drugpatentwatch.com/